Combining ADCs with immune checkpoint inhibitors, targeted therapies, and chemotherapy has yielded encouraging clinical results across a range of cancers, including HER2-positive breast cancer, triple-negative breast cancer, urothelial carcinoma, and lymphoma. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.